Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Golden Meditech and MD Anderson Form $20 Million Stem Cell Company

publication date: Sep 19, 2016
Golden Meditech, a Hong Kong company with a China cord blood banking subsidiary, formed an autoimmune-focused biotech, Cellenkos, with the University of Texas at MD Anderson Cancer Center. Cellenkos will combine the T-reg stem cell technology developed at the Anderson Center and Golden Meditech's banked cord blood samples. Golden Meditech, along with an unidentified strategic investor, invested $10 million in the newco and owns warrants to purchase an additional $10 million of shares. If they exercise the warrants, the investors will own 51% of Cellenkos. More details....

Stock Symbols: (HK: 00801; TW: 910801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital